Clinical Trial Update: Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating neurocognition in NSCLC patients treated with osimertinib or osimertinib plus whole-brain irradiation (WBI).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Osimertinib + WBI

Snippet

Sponsor: Sun Yat-sen University | Conditions: Neurocognitive | Phase 2 | Status: UNKNOWN